The National Institutes of Health (NIH) defines a Clinical Trial as a research study in which one or more human subjects are prospectively assigned to one or more interventions. Clinical trials help develop novel drugs (Investigational Products) by providing early access to patients who volunteer to participate in the research study.
Carolina BioOncology Institute and our expert Providers participate in the national clinical trials listed below. The eligibility criteria enables patients with advanced solid tumors to access these Investigational Products. Over the past 15 years, our Clinic has opened over 100 Oncology clinical trials and our experienced staff are happy to discuss options for determining trial eligibility Please view the list of trials below that are currently enrolling patients:
AbbVie M21-410
A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with ABBV-514 as a Single Agent and in Combination with Pembrolizumab or Budigalimab.
AbbVie M24-742
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
AbbVie M25-632
Phase 1 first-in-human, open-label study evaluating the safety, pharmacokinetics, and efficacy of ABBV-711 as a monotherapy or in combination with budigalimab (ABBV-181) in adult subjects with advanced squamous tumors
AbbVie M26-326
Phase 1, first-in-human, open-label study evaluating safety, pharmacokinetics, and efficacy of ABBV-253 in adult subjects with advanced solid tumors
ClinicalTrials.gov link still pending.
Acrivon ACR-2316-101
Phase 1 study of ACR-2316 in subjects with advanced solid tumors
Arvinas ARV-6723-101
A Phase 1/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ARV-6723 Administered as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
Aulos CP-AU-007-01
A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer
BioNTech BNT317-01
A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients with Advanced Solid Tumors
Conjupro JMT108-002
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JMT108 Injection in Participants with Advanced Malignant Tumors
CytoMx CTMX-2051-01
First In Human Study of CX-2051 in Advanced Solid Tumors
Dren Bio DR-0202-ONC-101
A Phase Ia/Ib, Multicenter, Dose Escalation/Expansion, Multiple Dose Study to Evaluate Safety and Activity of DR-0202 in Patients with Locally Advanced Metastatic, Relapsed, or Refractory Carcinomas
Duality Bio DB-1419-O-1001
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants with Advanced/Metastatic Solid Tumors
Duality Bio DB-1324-101
A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1324 in Participants with Advanced/Metastatic Gastrointestinal Tumors
EMD Serono MS743701_0001
A Phase 1, 2-Part, Multicenter, Open-Label, First-in-Human Study of the anti-Ly6E Exatecan Antibody-Drug Conjugate M7437 in Participants with Advanced Solid Tumors
ENSEM ETX-636-C-001
A Phase 1/2, Open-Label, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ETX-636, a Pan-Mutant-Selective PI3Kα Inhibitor, as Monotherapy and in Combination with Other Anticancer Therapies in Participants with Advanced Solid Tumors
Exelixis XB371-101
A Dose Escalation and Expansion Study of XB371 Administered in Participants with Locally Advanced or Metastatic Solid Tumors
Exelixis XB628-101
A Phase 1 Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Hansoh HS-20110-101
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20110 in Patients with Advanced Solid Tumors
Multitude Therapeutics AMT-116-01
AMT-116 in Patients With Advanced Solid Tumors
Multitude AMT-676-01
First-in-Human, Phase I/II Study of AMT-676, an Anti-CDH17 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors
Qurgen SON-DP-A001-ST
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Revolution Medicines RMC-9805-01
Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumor
Rondo Therapeutics RNDO-564-001
An Open-Label, Multicenter, Phase 1/1b Study of RNDO-564 as Monotherapy and in Combination with Pembrolizumab in Adult Participants with Relapsed/Refractory Locally Advanced or Metastatic Urothelial Cancer and Other Solid Tumors Associated with Nectin-4 Expression
Tasca TAS-CP383-01
A Multicenter, Open Label, Phase 1/2 Study of CP-383, an Oral Dual DHODH and TEAD4 Inhibitor, in Patients with Advanced or Metastatic Solid Tumors
Teva TV56278-ONC-10203
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Solid Tumors
Trethera TRE515-T-02
A Phase 1, Open-Label, First-In-Human, Dose-Escalation Study with Expansion to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered TRE-515 in Subjects with Solid Tumors.
Xadcera DM002001
A Phase I/IIa, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients with Advanced Solid Tumors
